secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001213900-25-031603
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt regains Nasdaq minimum bid price compliance, removes panel monitoring
----------------------------------------------------------------------------

- Regained full compliance with Nasdaq listing requirements; no longer under panel monitoring.
- Adimune subsidiary targeting IND/CTA filing for human trials in Q3/Q4 2025 for psoriasis and Type 1 diabetes.
- Pearsanta plans commercial launch of prostate cancer and endometriosis tests in H2 2025.
- Working to close Appili and Evofem acquisitions; capital and restructuring needed.
- CEO reports approximately 40,000-50,000 shareholders globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025031603/0001213900-25-031603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025031603/ea0238058-8k_aditxtinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-031603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer